8月7日 - ** Neuren Pharmaceuticals NEU.AX股价上涨8.4%至18.440澳元，创下自2024年8月2日以来的最高水平。
** 该药物开发商称其北美合作伙伴 Acadia Pharmaceuticals ACAD.O第二季度DAYBUE™(trofinetide) 的净销售额为9610万美元，比去年同期增长14%。
** 该药用于治疗雷特综合征等遗传性脑部疾病
** Neuren 预计第二季度从 DAYBUE 的销售中获得 1,470 万澳元的版税(957 万美元)，同比增长 16
** 公司已 授予 Acadia 公司开发和商业化 DAYBUE(trofinetide 的独家许可。)
** 今年以来，NEU 股价上涨了 44.2%，ACAD 股价上涨了 29.7
(1 美元 = 1.5363 澳元)
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.